EUVIMEDEUVIMED entdecken
Crossref

Development of Nickel Prussian Blue Analogue Nanoparticles Stabilizing the Glucocerebrosidase in the Treatment of Gaucher Disease (GD)

Sumit Manna, Lipi Pradhan, Akshita Singh, Pragya Pallavi, Suyash Baloni, Khushboo Bhagat, Aditya K Padhi iD, Sudip Mukherjee iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.5c23477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Sumit Manna und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, IIT (BHU), Varanasi 221005, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Ferrocyanides, Glucosylceramidase, Gaucher Disease, Nickel. Die Arbeit nennt 69 Literaturangaben. Gefördert von: ICMR, New Delhi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The stabilization of mutated glucocerebrosidase (GCase) in Gaucher disease (GD) remains an unresolved challenge in conventional therapies like enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), which are expensive and fail to treat neurological GD (nGD) forms. The misfolded enzyme fails to reach the lysosome and form aggregates, contributing to cellular stress. In the present work, a virtual screening of a metal ion library was reported, that enabled the identification of Ni2+ as the lead, demonstrating a high binding score to the active site of GCase. Nickel Prussian blue analogue nanoparticles (NiPB NPs) were synthesized, which showed an enhancement of GCase activity in the brain, liver, and spleen (∼35%, 25%, and 20%, respectively), higher than that of untreated CBE-induced GD mice. Improvement in the motor skills of GD mice highlights the potential of NiPB NP in managing nGD forms. The NiPB NP successfully elevated the residual activity of GCase (∼120% at 10 μg/mL dose) in the GBA1 siRNA knockdown HEK cell model. Finally, in an in vivo siRNA-mediated gene knockdown model, the NiPB NP enhanced the GCase activity in the organs significantly more than the untreated mice and alleviated GD symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerrocyanidesGlucosylceramidaseGaucher DiseaseNickelNanoparticlesAnimalsHumansMiceHEK293 Cells

Stichwörter der Autor:innen

GCaseGaucher diseasemetal ionsnanoparticlesnickel Prussian bluestabilizers

Substanzen

FerrocyanidesGlucosylceramidaseferric ferrocyanideNickel

Autor:innen und Institutionen

  • School of Biomedical Engineering, IIT (BHU), Varanasi 221005, Uttar Pradesh, India.
  • Laboratory for Computational Biology & Biomolecular Design, School of Biochemical Engineering, IIT (BHU), Varanasi 221005, Uttar Pradesh, India.

ORCID-Profile: Aditya K Padhi, Sudip Mukherjee

Förderung

  • ICMR, New Delhi

Zitieren

APA

Manna, S., Pradhan, L., Singh, A., Pallavi, P., Baloni, S., Bhagat, K., Padhi, A. K., & Mukherjee, S. (2026). Development of Nickel Prussian Blue Analogue Nanoparticles Stabilizing the Glucocerebrosidase in the Treatment of Gaucher Disease (GD). ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c23477

Vancouver

Manna S, Pradhan L, Singh A, Pallavi P, Baloni S, Bhagat K, et al. Development of Nickel Prussian Blue Analogue Nanoparticles Stabilizing the Glucocerebrosidase in the Treatment of Gaucher Disease (GD). ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c23477

BibTeX
@article{Manna2026,
  author = {Manna, Sumit and Pradhan, Lipi and Singh, Akshita and Pallavi, Pragya and Baloni, Suyash and Bhagat, Khushboo and Padhi, Aditya K and Mukherjee, Sudip},
  title = {Development of Nickel Prussian Blue Analogue Nanoparticles Stabilizing the Glucocerebrosidase in the Treatment of Gaucher Disease (GD)},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.5c23477}
}
Kostenlos starten →